Our study demonstrates for the first time that PPARγ is essential for EPO-induced improvements in hepatic insulin resistance, which supports the idea that EPO may contribute to a novel strategy for treating insulin resistance and type 2 diabetes. Here, PPARG is linked to Insulin resistance.